Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study.

Tadesse BT, Chala A, Mukonzo J, Chaka TE, Tadesse S, Makonnen E, Brumme ZL, Brumme CJ, Aklillu E.

Pathogens. 2019 Sep 24;8(4). pii: E161. doi: 10.3390/pathogens8040161.

2.

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Fotoohi A, Aseffa A, Howe R, Aklillu E.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1353. doi: 10.3390/cancers11091353.

3.

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia.

Tadesse BT, Tsai O, Chala A, Chaka TE, Eromo T, Lapointe HR, Baraki B, Shahid A, Tadesse S, Makonnen E, Brumme ZL, Aklillu E, Brumme CJ.

Viruses. 2019 Sep 19;11(9). pii: E877. doi: 10.3390/v11090877.

4.

Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.

Mikomangwa WP, Oms M, Aklillu E, Kamuhabwa AAR.

BMC Pregnancy Childbirth. 2019 Jul 8;19(1):236. doi: 10.1186/s12884-019-2397-1.

5.

CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, Aseffa A, Howe R, Fotoohi A, Hassan M, Aklillu E.

Front Pharmacol. 2019 May 14;10:481. doi: 10.3389/fphar.2019.00481. eCollection 2019.

6.

Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.

Mukonzo J, Aklillu E, Marconi V, Schinazi RF.

Int J Infect Dis. 2019 Jun;83:98-101. doi: 10.1016/j.ijid.2019.04.009. Epub 2019 Apr 13.

7.
8.

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children.

Tadesse BT, Foster BA, Chala A, Chaka TE, Bizuayehu T, Ayalew F, H/Meskel G, Tadesse S, Jerene D, Makonnen E, Aklillu E.

J Clin Med. 2019 Mar 28;8(4). pii: E430. doi: 10.3390/jcm8040430.

10.

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia.

Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, Tigeneh W, Aseffa A, Howe R, Aklillu E.

Nutrients. 2019 Jan 29;11(2). pii: E289. doi: 10.3390/nu11020289.

11.

Conference report: pharmacogenomics in special populations at WCP2018.

Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA.

Br J Clin Pharmacol. 2019 Mar;85(3):467-475. doi: 10.1111/bcp.13828. Epub 2019 Jan 24. Review.

PMID:
30537134
12.

Cigarette smoking and heavy coffee consumption affecting response to olanzapine: the role of genetic polymorphism.

Djordjevic N, Radmanovic B, Cukic J, Baskic D, Djukic-Dejanovic S, Milovanovic D, Aklillu E.

World J Biol Psychiatry. 2018 Dec 4:1-53. doi: 10.1080/15622975.2018.1548779. [Epub ahead of print]

PMID:
30513034
13.

Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study.

Tadesse BT, Foster BA, Kabeta A, Ayalew F, H/Meskel G, Jerene D, Makonnen E, Aklillu E.

HIV Med. 2019 Feb;20(2):147-156. doi: 10.1111/hiv.12693. Epub 2018 Nov 26.

PMID:
30474906
14.

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E.

Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.

15.

Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Bedada W, de Andrés F, Engidawork E, Hussein J, LLerena A, Aklillu E.

Sci Rep. 2018 Aug 24;8(1):12726. doi: 10.1038/s41598-018-31191-1.

16.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

17.

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N.

Eur J Clin Pharmacol. 2018 Jul;74(7):903-911. doi: 10.1007/s00228-018-2448-y. Epub 2018 Mar 27.

18.

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, Brumme CJ, Foster BA, Jerene D, Makonnen E, Aklillu E, Brumme ZL.

Viruses. 2018 Feb 1;10(2). pii: E60. doi: 10.3390/v10020060.

19.

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, Färnert A, Aklillu E.

Malar J. 2017 Jul 3;16(1):267. doi: 10.1186/s12936-017-1914-9.

20.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

21.

Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Petros Z, Lee MT, Takahashi A, Zhang Y, Yimer G, Habtewold A, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

OMICS. 2017 Apr;21(4):207-216. doi: 10.1089/omi.2017.0019.

22.

HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.

Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E.

Front Pharmacol. 2017 Feb 27;8:90. doi: 10.3389/fphar.2017.00090. eCollection 2017.

23.

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Petros Z, Makonnen E, Aklillu E.

OMICS. 2017 Mar;21(3):123-131. doi: 10.1089/omi.2017.0006. Epub 2017 Feb 16.

24.

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Aderaye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

BMC Genomics. 2016 Sep 26;17(1):755.

25.

SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.

Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J.

OMICS. 2016 Sep;20(9):538-45. doi: 10.1089/omi.2016.0119.

PMID:
27631193
26.

Conference Report: First Pharmacogenetics and Precision Medicine Conference in Africa (April 7-9, 2016, Cape Town, South Africa).

Dandara C, Suarez-Kurtz G, Aklillu E.

OMICS. 2016 Sep;20(9):496-7. doi: 10.1089/omi.2016.0128. No abstract available.

PMID:
27631188
27.

Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking.

Dandara C, Endrenyi L, Kolker E, Hekim N, Steuten LM, Güngör K, Aklillu E, Özdemir V.

OMICS. 2016 Sep;20(9):493-5. doi: 10.1089/omi.2016.0129. No abstract available.

PMID:
27631187
28.

High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.

Desta K, Woldeamanuel Y, Azazh A, Mohammod H, Desalegn D, Shimelis D, Gulilat D, Lamisso B, Makonnen E, Worku A, Mannerqvist K, Struwe J, Aspevall O, Aklillu E.

PLoS One. 2016 Aug 30;11(8):e0161685. doi: 10.1371/journal.pone.0161685. eCollection 2016.

29.

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Medicine (Baltimore). 2016 Aug;95(34):e4631. doi: 10.1097/MD.0000000000004631.

30.

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, Fier I, Kampf C, Göpfert J, Perazzo H, Poynard T, Stephens C, Andrade RJ, Lucena MI, Arber N, Uhlén M, Watkins PB, Schwenk JM, Nilsson P, Schuppe-Koistinen I.

Liver Int. 2017 Jan;37(1):132-140. doi: 10.1111/liv.13174. Epub 2016 Jun 22.

31.

Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women.

Mutagonda RF, Kamuhabwa AA, Minzi OM, Massawe SN, Maganda BA, Aklillu E.

Malar J. 2016 May 13;15(1):278. doi: 10.1186/s12936-016-1327-1.

32.

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.

J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.

PMID:
27125860
33.

An Open Letter in Support of Transformative Biotechnology and Social Innovation: SANKO University Innovation Summit in Medicine and Integrative Biology, Gaziantep, Turkey, May 5-7, 2016.

Saygılı Eİ, Abou-Zeid AH, Akkın SM, Aklillu E, Barlas İÖ, Borda-Rodriguez A, Boschele FA, Çetin Z, Coşkun E, Coşkun Y, Dağlı G, Dai TU, Dandara C, Dereli T, Elbeyli L, Endrenyi L, Eyigün CP, Georgakilas A, Günbulut B, Güngör K, Güzelbey A, Hekim C, Huzair F, Kimyon S, Karakaş Ü, Lin B, LLerena A, Masimirembwa C, McNally R, Mete A, Sancar P, Srivastava S, Steuten LM, Tanrıöver O, Tyfield D, Töre Vİ, Vuruşkan D, Wang W, Warnich L, Wonkam A, Yıldırım YZ, Yılmaz İ, Sınav A, Hekim N.

OMICS. 2016 Apr;20(4):259-62. doi: 10.1089/omi.2016.0038. No abstract available.

PMID:
27093110
34.

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.

Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, Aklillu E.

Pharmacogenomics. 2016 Apr;17(6):603-13. doi: 10.2217/pgs.16.7. Epub 2016 Apr 5.

PMID:
27045425
35.

miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.

Ekström L, Skilving I, Ovesjö ML, Aklillu E, Nylén H, Rane A, Diczfalusy U, Björkhem-Bergman L.

Pharmacol Res Perspect. 2015 Oct 27;3(6):e00192. doi: 10.1002/prp2.192. eCollection 2015 Dec.

36.
37.

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.

Bedada W, de Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, Llerena A, Aklillu E.

J Clin Psychopharmacol. 2015 Dec;35(6):694-9. doi: 10.1097/JCP.0000000000000413.

PMID:
26444948
38.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
39.

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, Schuetz EG.

Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28.

40.

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.

Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E.

OMICS. 2015 Jun;19(6):346-53. doi: 10.1089/omi.2015.0022. Epub 2015 May 15.

PMID:
25977991
41.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

42.

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.

Maganda BA, Minzi OM, Ngaimisi E, Kamuhabwa AA, Aklillu E.

Pharmacogenomics J. 2016 Feb;16(1):88-95. doi: 10.1038/tpj.2015.37. Epub 2015 May 12.

PMID:
25963334
43.
44.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

45.

Genesis of EDCTP2.

Zumla A, Makanga M, Nyirenda T, Beattie P, Olesen OF, Breugelmans JG, Aklillu E, Corrah T, Mgone C.

Lancet Infect Dis. 2015 Jan;15(1):11-3. doi: 10.1016/S1473-3099(14)71034-5. Epub 2014 Dec 2. No abstract available.

PMID:
25477021
46.

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.

Mukonzo JK, Nanzigu S, Waako P, Ogwal-Okeng J, Gustafson LL, Aklillu E.

Pharmacogenomics. 2014 Aug;15(11):1423-35. doi: 10.2217/pgs.14.73.

PMID:
25303294
47.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U.

J Antimicrob Chemother. 2014 Dec;69(12):3311-9. doi: 10.1093/jac/dku286. Epub 2014 Aug 4.

PMID:
25096076
48.

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Aug;24(8):409-25. doi: 10.1097/FPC.0000000000000062. Review. No abstract available.

49.

Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.

Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, Aderaye G, Schuppe-Koistinen I, Lindquist L, Aklillu E.

PLoS One. 2014 Apr 8;9(4):e94271. doi: 10.1371/journal.pone.0094271. eCollection 2014.

50.

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, Thabane L, Gustafsson LL, Ross C, Aklillu E.

PLoS One. 2014 Jan 31;9(1):e86919. doi: 10.1371/journal.pone.0086919. eCollection 2014.

Supplemental Content

Loading ...
Support Center